1. Home
  2. FT vs NGEN Comparison

FT vs NGEN Comparison

Compare FT & NGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Franklin Universal Trust

FT

Franklin Universal Trust

HOLD

Current Price

$7.97

Market Cap

199.8M

Sector

Finance

ML Signal

HOLD

NGEN

NervGen Pharma Corp. Common stock

N/A

Current Price

$1.89

Market Cap

175.1M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
FT
NGEN
Founded
1988
2017
Country
United States
Canada
Employees
N/A
9
Industry
Trusts Except Educational Religious and Charitable
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
199.8M
175.1M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
FT
NGEN
Price
$7.97
$1.89
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$18.00
AVG Volume (30 Days)
46.9K
1.1M
Earning Date
01-01-0001
04-02-2026
Dividend Yield
7.85%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.43
$1.91
52 Week High
$8.35
$5.93

Technical Indicators

Market Signals
Indicator
FT
NGEN
Relative Strength Index (RSI) 41.14 22.21
Support Level $7.82 N/A
Resistance Level $8.05 $4.52
Average True Range (ATR) 0.07 0.15
MACD -0.00 -0.13
Stochastic Oscillator 44.68 1.00

Price Performance

Historical Comparison
FT
NGEN

About FT Franklin Universal Trust

Franklin Universal Trust is a closed-end management investment company focused on providing high current income while preserving capital. Its secondary objective is to achieve income growth through dividend increases and capital appreciation. The fund invests in two asset classes: high-yield bonds and utility stocks. It applies fundamental research to build a diversified high-yield bond portfolio and targets utility companies with attractive dividend yields and a history of increasing dividends.

About NGEN NervGen Pharma Corp. Common stock

NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.

Share on Social Networks: